Business
Delhi High Court allows Sun Pharma to manufacture and export Ozempic-like drug, but no sale in India
The Court noted the defendant’s assurance that its semaglutide product will only be exported to markets where Novo Nordisk does not hold patent protection.
“Export to countries in which they don’t have patent. That is the affidavit in that matter,” the judge said, directing Sun Pharma to file an affidavit within two weeks to formally confirm the undertaking.
During the hearing, Sun Pharma acknowledged that it is already producing the drug.
Justice Arora directed that the company file quarterly account statements reflecting export or other relevant figures through March 2026, mirroring directions given in the earlier suit.